March 2019. Volume 15. Number 1

Management of non-severe exacerbations in children with bronchiectasis: what’s new?

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Goyal V, Grimwood K, Byrnes CA, Morris PS, Masters IB, Ware RS, et al. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomized controlled trial. Lancet. 2018;392;1197-206.

Reviewers: Molina Arias M1, Rivas Fernández MÁ2.
1Servicio de Gastroenterología. Hospital Infantil Universitario La Paz. Madrid. España.
2Hospital Universitario General de Cataluña. Sant Cugat del Vallés. Barcelona. España.
Correspondence: Manuel Molina Arias. Email: mma1961@gmail.com
Reception date: 09/01/2019
Acceptance date: 18/01/2019
Publication date: 06/02/2019

Abstract

Authors’ conclusions: azithromycin provides another therapeutic option in patients with bronchiectasis and mild exacerbation, allergic to penicillin or with poor compliance with medical orders; although it should be considered that it leads to longer duration of symptoms, as well as greater risk of therapeutic failure and of inducing resistance to macrolides, with respect to amoxicillin-clavulanate acid.

Reviewers’ commentary: azithromycin may be a second-choice alternative for the treatment of children with bronchiectasis and mild or moderate exacerbations, in the absence of other severity factors such as cystic fibrosis or Pseudomonas aeruginosa infection.

How to cite this article

Molina Arias M, Ángeles Rivas-Fernández M. Manejo de las exacerbaciones no graves en niños con bronquiectasias: ¿qué hay de nuevo? Evid Pediatr. 2019;15:4.

AVC | Critically appraised articles

Goyal V, Grimwood K, Byrnes CA, Morris PS, Masters IB, Ware RS, et al. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomized controlled trial. Lancet. 2018;392;1197-206.

Reviewers: Molina Arias M1, Rivas Fernández MÁ2.
1Servicio de Gastroenterología. Hospital Infantil Universitario La Paz. Madrid. España.
2Hospital Universitario General de Cataluña. Sant Cugat del Vallés. Barcelona. España.
Correspondence: Manuel Molina Arias. Email: mma1961@gmail.com
Reception date: 09/01/2019
Acceptance date: 18/01/2019
Publication date: 06/02/2019

How to cite this article

Molina Arias M, Ángeles Rivas-Fernández M. Manejo de las exacerbaciones no graves en niños con bronquiectasias: ¿qué hay de nuevo? Evid Pediatr. 2019;15:4.

06/02/2019

Linked Comment